Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the.

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024. Details of the event are as follows: Panel: “Off-the-Shelf CART – Let's Talk Lupus an.

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Adicet Bio (ACET) Stock Might be a Great Pick

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

Arbe Robotics Ltd

KORU Medical Systems Inc

Lantronix

CarParts.com, Inc.

PowerFleet Inc

Vor Biopharma

In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.

The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness

The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Adicet Bio (NASDAQ: ACET ) just reported results for the fourth quarter of 2023. Adicet Bio reported earnings per share of -69 cents.

ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023. “We are excited to explore the potential of our gamma delta T cell platform in autoimmune diseases following the FDA's IND clearance of ADI-001 in lupus nephri.

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference being held March 26, 2024. Details of the event are as follows: Date: Tuesday, March 26, 2024 Time: 10.

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Hive Blockchain Technologies Ltd

SoundHound AI Inc

High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the market's appetite for risk continues to grow.

3 High-Risk Stocks That Could Pay Off in the Millions

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?

Arcadium Lithium PLC

BigBear.ai Holdings

Hanesbrands

Himax Tech

Pitney Bowes

Penny stocks are heating up as the S&P 500 hits new highs, signaling opportunity. With the S&P 500 posting new highs multiple times in the past few months and prospects of lower interest rates, the stage is set for potentially lucrative penny stock investments.

7 Top-Tier Penny Stocks for a Smart Bet

Actinium Pharmaceuticals

Cara Therapeutics

Clearside Biomedical

Karyopharm Therapeutics

Outlook Therapeutics Inc

Stoke Therapeutics Inc

While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference being held from February 7-8, 2024 in New York. Details of the event are as follows: Date: Thursd.

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

ArriVent Biopharma Inc

CG oncology Inc

Corbus Pharmaceuticals Holdings

Arcus Biosciences

Vera Therapeutics

As January wound to a close, the most notable insider purchases were in biopharma companies, particularly those with initial or secondary offerings of stock.

Insider Buying at These Biotechs Is Huge

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the closing of its previously announced underwritten public offering of 32,379,667 shares of its common stock, which includes 5,325,000 shares sold and issued upon the exercise in full by the underwriters of their option to purchase additional shares of common.

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten public offering of 27,054,667 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,445,333 shares of common stock. The shares of common stock are being sold at.

Adicet Bio, Inc. Announces Pricing of Public Offering

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. The purchase price of each pre-funded warrant will equal the pri.

Adicet Bio, Inc. Announces Proposed Public Offering

Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024.

Adicet (ACET) Stock Rallies 130% in a Month: Here's Why

Adicet Bio, Inc. (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adicet Bio, Inc. (ACET) Upgraded to Buy: Here's Why

Clinical updates for its CAR-T programs ADI-001 for lupus nephritis and mantle cell lymphoma are expected in the second half of 2024. ADI-001 has shown promising results in late-line MCL patients, with high response rates and a good safety profile. ADI-001 has the potential to be used in the treatment of other autoimmune disorders, including lupus nephritis.

Adicet Bio: Clinical Updates In 2H 2024 Makes This A Must-Watch

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate updates and highlighted upcoming priorities for its pipeline programs in 2024. “In 2024, we aim to make significant strides across our pipeline of differentiated gamma delta T cell therapies through our strategic and disciplined approach,” said Chen S.

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call and Webcast Event The live webcast of the presentation can be accessed by registering u.

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

News for Adicet Bio, Inc. Stock (ACET)